Compare Ferrari NV (RACE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Recursion Pharmaceuticals Inc — how do they compare? Ferrari NV trades at $371.61 (market cap $65.25B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: Ferrari NV is far larger — about 40× Recursion Pharmaceuticals Inc's market cap, and Ferrari NV pays a 1.14% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RACE | RXRX | |
|---|---|---|
Market Cap | $65.25B | $1.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $517.65 | $6.79 |
52-Week Low | $314.63 | $2.84 |
Enterprise Value | $66.46B | $1.05B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $369.97, down 1.82% today, with a bullish technical outlook supported by moving averages and key support at $370. The company demonstrates strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow from operations of $2.35B in 2025. Recent news highlights ongoing share buybacks and the upcoming Q2 2026 earnings report on July 30.
The investment outlook remains positive given Ferrari's premium brand positioning, pricing power, and analyst consensus price target of $467.50 implying 26% upside. Risks include execution challenges with new EV models, economic sensitivity, and high valuation multiples. Wall Street sentiment is strongly bullish with 72% buy ratings.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
